Unzyme Laboratories has released its 2025 Annual Safety Report, providing a transparent overview of safety outcomes across all commercial products and active clinical trials. The report demonstrates continued excellence in patient welfare metrics, with key indicators remaining well within acceptable parameters.
Key Findings
Commercial Products
Our portfolio of approved enhancement technologies maintained strong safety profiles throughout 2025:
- SynthCortex II: 99.2% of users reported no serious adverse events
- OptiLens Pro: Visual acuity improvements sustained with minimal side effects
- ExoFrame Mk IV: Zero structural failures reported in over 12,000 active units
- NeuroLink Interface: Connectivity issues reduced by 73% compared to previous year
Clinical Trial Safety
Across our 14 active clinical trials, involving over 8,700 participants globally:
- Serious adverse event rate: 0.3% (industry average: 2.1%)
- Trial discontinuation due to adverse events: 1.2%
- All serious events fully resolved within established protocols
Transparency Commitment
As part of our ongoing commitment to transparency, the full safety report has been submitted to relevant regulatory authorities in all jurisdictions where we operate. Summary data is available upon request for healthcare providers and institutional partners.
“Safety isn’t just a regulatory requirement—it’s fundamental to our mission,” stated Dr. Marcus Chen, Head of Pharmacovigilance. “Every participant and patient trusts us with their wellbeing. That trust drives everything we do.”
Continuous Improvement
While our safety outcomes exceed industry benchmarks, we continue to invest in improvements:
- Enhanced real-time monitoring systems deployed across all trial sites
- New predictive algorithms for early adverse event detection
- Expanded post-market surveillance for commercial products
- Additional training programs for clinical staff
Reporting Concerns
We encourage all patients and healthcare providers to report any concerns through our dedicated safety reporting channels:
- Emergency Line: Available 24/7 for urgent concerns
- Online Portal: safety.unzyme.com
- Healthcare Provider Hotline: Direct access for medical professionals
The full 2025 Annual Safety Report is available for download from our publications page.